Magazine Article | February 1, 2019

Why Patent Protection Is Key To Commercializing Repurposed Drugs

Source: Life Science Leader

By John Conour

If you’ve been involved in any aspect of drug development in your career, it’s likely you are aware that, on average, only 1 in 10 therapeutic candidates that enter Phase 1 clinical trials is approved. Consequently, the industry is littered with abandoned, shelved drugs, or drugs simply listed as “failures.”

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: